<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700631</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0104</org_study_id>
    <nct_id>NCT04700631</nct_id>
  </id_info>
  <brief_title>Extracellular Vesicles as Biomarkers for Chronic Renal Failure</brief_title>
  <acronym>VE-IRC</acronym>
  <official_title>Extracellular Vesicles as Biomarkers for Chronic Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recent discovery of extracellular vesicles (EV) as a mechanism of intercellular&#xD;
      communication has made it possible to develop a new field of health research and could bring&#xD;
      new information on the pathological mechanisms of renal diseases. Definition of physiologic&#xD;
      and pathologic values of urinary extracellular vesicles (EVu) between healthy subjects and&#xD;
      chronic kidney diseases (CKD) patients could be a new tool for follow up of renal diseases.&#xD;
      EV are found in all biological fluids including urine, that's why they are increasingly&#xD;
      analyzed in renal pathologies. The main objective of this study is to determine the&#xD;
      physiological values and the pathological thresholds of EVu.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>variation of urinary extracellular vesicle concentration between both groups</measure>
    <time_frame>one day</time_frame>
    <description>variation of urinary extracellular vesicle concentration between both groups : healthy and CRF patients Urinary extracellular vesicle concentrations will be measured as number of extracellular vesicles per mL of urine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Renal Failure</condition>
  <condition>Urinary Extracellular Vesicle</condition>
  <arm_group>
    <arm_group_label>healthy subject</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy subjects : no medical history, in particular cardiovascular, without drug treatment, without proteinuria, normal BMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRF patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRF patients : eGFR estimated according to the MRDR formula less than 89 mL/min/1,73m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>urinary extracellular vesicle concentration</intervention_name>
    <description>urinary extracellular vesicle concentration will be determined in urine samples from CRF and healthy patients</description>
    <arm_group_label>CRF patients</arm_group_label>
    <arm_group_label>healthy subject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample in order to determine creatin level</description>
    <arm_group_label>CRF patients</arm_group_label>
    <arm_group_label>healthy subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subject &gt; 18 years old&#xD;
&#xD;
          -  healthy subjects : no medical history, in particular cardiovascular, without drug&#xD;
             treatment, without proteinuria, normal BMI&#xD;
&#xD;
          -  CRF patients : eGFR estimated according to the MRDR formula less than 89 mL/min/1,73m²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients under dialysis protocols&#xD;
&#xD;
          -  renal transplant patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas GUILLAUME, Pr</last_name>
    <phone>(33)3.22.08.70.46</phone>
    <email>guillaume.nicolas@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire PRESNE, MD</last_name>
    <phone>(33)3.22.45.62.19</phone>
    <email>presne.claire@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Guillaume, Pr</last_name>
      <phone>(33)3.22.08.70.46</phone>
      <email>guillaume.nicolas@chu-amiens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire PRESNE</last_name>
      <phone>(33)3.22.45.62.19</phone>
      <email>presne.claire@chu-amiens.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary extracellular vesicle</keyword>
  <keyword>Chronic Renal Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

